Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

<p>Abstract</p> <p>Background</p> <p>Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple scleros...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
Format: Artigo
Langue:Inglês
Publié: BMC 2012-12-01
Collection:Health and Quality of Life Outcomes
Sujets:
Cognitive function
Health-related quality of life
Multiple sclerosis
Natalizumab
Patient-reported outcomes
Accès en ligne:http://www.hqlo.com/content/10/1/155
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires